These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Incorporating historical information to improve phase I clinical trials. Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044 [TBL] [Abstract][Full Text] [Related]
48. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model. Zhao D; Zhu J; Wang L Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097 [TBL] [Abstract][Full Text] [Related]
49. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096 [TBL] [Abstract][Full Text] [Related]
50. Flexible use of copula-type model for dose-finding in drug combination clinical trials. Hashizume K; Tshuchida J; Sozu T Biometrics; 2022 Dec; 78(4):1651-1661. PubMed ID: 34181760 [TBL] [Abstract][Full Text] [Related]
51. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy. Zhang D; Xu J Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934 [TBL] [Abstract][Full Text] [Related]
52. Keyboard design for phase I drug-combination trials. Pan H; Lin R; Zhou Y; Yuan Y Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751 [TBL] [Abstract][Full Text] [Related]
53. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Yin J; Paoletti X; Sargent DJ; Mandrekar SJ Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555 [TBL] [Abstract][Full Text] [Related]
54. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Zang Y; Lee JJ; Yuan Y Clin Trials; 2014 Jun; 11(3):319-327. PubMed ID: 24844841 [TBL] [Abstract][Full Text] [Related]
55. CFO: Calibration-free odds design for phase I/II clinical trials. Jin H; Yin G Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697 [TBL] [Abstract][Full Text] [Related]
56. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group. Chen Z; Krailo MD; Sun J; Azen SP; Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782 [TBL] [Abstract][Full Text] [Related]
57. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations. Kakizume T; Takeda K; Taguri M; Morita S Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354 [TBL] [Abstract][Full Text] [Related]
58. Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy. Nie L; Rubin EH; Mehrotra N; Pinheiro J; Fernandes LL; Roy A; Bailey S; de Alwis DP Clin Cancer Res; 2016 Jun; 22(11):2623-9. PubMed ID: 27250933 [TBL] [Abstract][Full Text] [Related]
59. Escalation with overdose control for phase I drug-combination trials. Shi Y; Yin G Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103 [TBL] [Abstract][Full Text] [Related]